Latest Developments and Insights on ADCs for Lung Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.50
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
Expanding the Applicability Beyond HER2m and EGFRm: TROP-2–Targeted ADCs in NSCLC and ADCs in Patients with SCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Mapping TROP-2–Targeted ADCs Into the NSCLC Treatment Landscape

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: ​Integrating a New Therapeutic Option

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.25
Antibody–Drug Conjugates and the Role of TROP-2 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
The Potential of Antibody‒Drug Conjugates Targeting CEACAM5 in NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Research Focus: Targeting CEACAM5 With Novel Antibody-Drug Conjugates in Nonsquamous Non-Small-Cell-Lung Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--